ClinicalTrials.gg
Not yet recruitingNCT05730595FLORA-01Updated Aug 29, 2023

Fluorescence Laparoscopic Navigation for Rectal Cancer and Sigmoid Colon Cancer

An interventional study of lymph node dissection in Colorectal Neoplasms, Fluorescence and Lymph Node Excision, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Not yet recruiting at 19 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-08-29.

Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
550
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 27 studies in Colorectal Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences — 21 open to participants now, 22 under way, 1 of them phase 3. Colorectal Neoplasms · Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

Planned enrollment
2nd of 17
550 · median 102
Started
2023
with 8 others
No phase
2 of 27
2 open now
Primary completion
2026-12
later than 15 of 21 live
Registered
6th of 27
by date

Among the 27 studies in Colorectal Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, this one is the 2nd largest by planned enrollment of the 17 interventional ones that give a count, is one of 9 that started in 2023, is one of 2 with no phase, reaches primary completion later than 15 of the 21 other live ones, and was the 6th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

21 of the 27 studies in Colorectal Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences are open now, in 1 country. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

Where they have run

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Colorectal Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, or all of them as a file.
02

Study summary

To explore the short-term and long-term outcomes of fluorescence laparoscopic navigation D2 lymph node dissection for colorectal cancer surgery by comparing it with D3 lymph node dissection.

Read the detailed description

Lymph node metastasis is the most common metastatic mechanisms for colorectal cancer. Therefore, regional lymph node dissection is the key part in radical surgery for colorectal cancer. In patients who have developed lymph node metastases, inadequate lymph node dissection will promote tumor recurrence. In patients who do not develop lymph node metastases, excessive lymph node dissection not only does not improve the patient's prognosis, but also increases surgical trauma and destroys the antitumor effect of the lymphoid immune system. There is still some controversy over whether to choose D3 lymph node dissection or D2 lymph node dissection for rectal and sigmoid cancer. Fluorescence laparoscopic navigation techniques can guide lymph node dissection by visualizing lymph nodes more clearly during surgery.

This study will compare the short-term and long-term oncological outcomes between fluorescence laparoscopic navigation D2 and D3 lymph node dissection by conducting a randomized controlled trial.

03

Conditions studied

  • Colorectal Neoplasms
  • Fluorescence
  • Lymph Node Excision

Keywords

  • Colorectal cancer
  • Fluorescence laparoscopic navigation
  • Lymph node dissection
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants are aged 18-75;
  • Colonoscopy confirms colorectal adenocarcinoma;
  • Colonoscopy shows that the lower edge of the tumor is located more than 10 cm from the margin or the tumor is located in the upper rectum and sigmoid colon by imaging diagnosis;
  • The tumor is staged cT1-4aNxM0 by preoperative imaging;
  • Participants have no local complications before surgery.

Exclusion criteria

Exclusion Criteria:

  • Previous history of malignant colorectal tumor;
  • Multiple primary colorectal tumors;
  • Preoperative imaging reveals suspicious positive lymph nodes in the submesenteric artery root region (area 253);
  • Patients undergoing therapy before surgery;
  • With to laparoscopic surgery;
  • Histoty of multiple abdominal and pelvic surgery or extensive abdominal adhesions;
  • Other were diagnosed within the past 5 years;
  • History of severe mental illness;
  • Pregnant or lactating women;
  • With uncontrolled infection before surgery.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
550 participants (estimated)

Study arms

  • Experimental
    D2 lymph node dissection

    The D2 lymph node region are dissected. And 1-3 lymph nodes of the D2 region will be selected for intraoperative frozen section. If no lymph node metastasis is found in freezing, the D3 region lymph nodes in the root of the submesenteric artery were preserved.

    Procedure: lymph node dissection

  • Active comparator
    D3 lymph node dissection

    Thorough dissection of lymph nodes in the D3 region.

    Procedure: lymph node dissection

Interventions

  • Procedurelymph node dissection

    The extent of lymph node dissection varies between groups

    Also known as: Fluorescence-guided laparoscopic surgery, Radical operation for rectal cancer and sigmoid Cancer

06

What researchers measure

Primary outcomes

  1. Disease-free survival

    Disease-free survival is defined as the time from the surgery to disease recurrence or last follow-up, which was measured in months.

    Time frame: The endpoint of the disease-free survival assessment is the last follow-up or disease recurrence. Follow-up time is up to 36 months.

  2. Overall survival

    Overall survival is defined as the time from the surgery to death or last follow-up, regardless of disease recurrence, which was measured in months.

    Time frame: The endpoint of the overall survival assessment is the last follow-up or patient death. Follow-up time is up to 36 months.

Secondary outcomes

  1. The number of lymph node resection

    The number of lymph nodes removed during surgery, which is obtained by postoperative pathological results

    Time frame: Until the pathological result is available , an average of 14 days.

  2. Blood loss

    Blood loss is defined as intraoperative blood loss and measured in milliliters(ml).

    Time frame: Until the end of the operation, an average of 8 hours.

  3. Complications

    Complications are defined as all surgery-related adverse events postoperatively, such as anastomotic leak, infection, which are measured in frequency.

    Time frame: Until the patient recovered and was discharged from the hospital, an average of 10 days.

  4. Hospital stay after surgery

    Hospital stay after surgery is defined as the length of time from the end of surgery

    Time frame: Until the patient recovered and was discharged from the hospital, an average of 10 days.

  5. Function score

    Function score includes International Prostate Symptom Score, low anterior resection syndrome score and International Index of Erectile Function-5 score, which are used for assess the physical function.

    Time frame: Until one year after the patient's surgery

07

Study locations

19 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2023; primary completion for Dec 2026, 39 months later.

Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 39 months is above that.

Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2023
First posted
Feb 16, 2023
StartEst.
Sep 1, 2023
Primary completionEst.
Dec 1, 2026
CompletionEst.
Jun 1, 2027
Last update
Aug 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05730595
Collaborators
Fudan University, Fujian Province Tumor Hospital, Guangdong Provincial People's Hospital, Shengjing Hospital, Affiliated Hospital of Qinghai University, Hebei Medical University Fourth Hospital, The Second Affiliated Hospital of Harbin Medical University, Jiangxi Provincial Cancer Hospital, The First Hospital of Jilin University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Shanxi Province Cancer Hospital, Nanfang Hospital, Southern Medical University, Second People's Hospital of Yunnan Province, Binzhou Medical University, The First Affiliated Hospital of University of Science and Technology of China, First Affiliated Hospital of Chengdu Medical College, The Second People's Hospital of Yibin, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Responsible party
Jianqiang Tang (Associate professor, Cancer Institute and Hospital, Chinese Academy of Medical Sciences) — Principal investigator
First posted
Feb 16, 2023
Start date
Sep 1, 2023 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Aug 29, 2023

Study contacts

Jianqiang Tang, Dr.
Contact
doc_tjq@hotmail.com
+8613661090036

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion